Europeans consider citalopram dosing after FDA action and Canadian review
This article was originally published in Scrip
Executive Summary
The UK medicines regulator is working with other European regulatory authorities to decide whether to restrict the maximum daily dose of the antidepressant citalopram following action taken in North America in light of heart safety data.